tumor RNA transfected dendritic cells

Tumor RNA transfected dendritic cells are a form of personalized cell-based immunotherapy in which autologous (patient-derived) dendritic cells are harvested and then ex vivo transfected with messenger RNA (mRNA) derived from the patient’s own tumor. The process involves isolating total mRNA from a macrodissected biopsy sample of the tumor and introducing it into the patient’s own cultured dendritic cells, typically via electroporation. These modified dendritic cells present a broad repertoire of tumor antigens to T-cells upon re-infusion into the patient, thereby stimulating a polyclonal anti-tumor immune response. This approach is designed to overcome limitations associated with vaccines targeting single or limited antigens and can be applied even when specific tumor antigens are unknown or insufficient tissue is available for peptide/protein isolation. Clinical trials have demonstrated safety and feasibility across multiple cancer types including melanoma, renal cell carcinoma, leukemia, brain tumors, prostate cancer, pancreatic cancer, and others[1][2][3]. The therapy remains investigational.

Other names

tumor mRNA-transfected dendritic cellsex vivo RNA-transfected dendritic cellsmRNA-electroporated dendritic cells